-logo-1200x675.png?v=20240604092546){kind=logo}
Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Free Report) – Analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Swedish Orphan Biovitrum in a research report issued on Friday, September 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of $0.62 per share for the quarter, down from their previous estimate of $0.63. The consensus estimate for Swedish Orphan Biovitrum’s current full-year earnings is $1.94 per share. HC Wainwright also issued estimates for Swedish Orphan Biovitrum’s Q4 2026 earnings at $0.59 EPS, FY2026 earnings at $1.91 EPS, Q1 2027 earnings at $0.61 EPS, Q3 2027 earnings at $1.04 EPS, Q4 2027 earnings at $1.01 EPS and FY2027 earnings at $3.31 EPS.
Other equities analysts also recently issued reports about the company. Pareto Securities downgraded Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Finally, Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.
Swedish Orphan Biovitrum Stock Performance
OTCMKTS:BIOVF opened at $48.13 on Wednesday. Swedish Orphan Biovitrum has a twelve month low of $29.18 and a twelve month high of $49.03. The stock has a market cap of $17.13 billion, a P/E ratio of 106.95 and a beta of 0.33. The firm’s fifty day simple moving average is $48.39 and its 200 day simple moving average is $45.63. The company has a quick ratio of 0.55, a current ratio of 0.88 and a debt-to-equity ratio of 0.20.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Swedish biopharmaceutical company focused on developing, manufacturing and commercializing therapies for rare diseases. Its principal areas of activity include hematology, immunology and specialty care, with an emphasis on conditions that have limited treatment options and relatively small patient populations.
Sobi’s portfolio includes treatments for hemophilia and other bleeding disorders, such as Elocta, Alprolix and Vonvendi, as well as medicines for immune-mediated and hematologic conditions.
Recommended Stories
- Five stocks we like better than Swedish Orphan Biovitrum
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.
